A new respirable form of rifampicin

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 78, Issue 3, 2011, Pages 366-376

  Son, Yoen Ju ^a   McConville, Jason T ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Crystal; Hydrate and dry powder inhaler; Polymorphism; Pulmonary; Rifampicin; Tuberculosis

Indexed keywords

RIFAMPICIN;

ARTICLE; BIODEGRADATION; CRYSTALLIZATION; LUNG INFECTION; POLYMORPHIC LOCUS;

ADMINISTRATION, INHALATION; AEROSOLS; ANTIBIOTICS, ANTITUBERCULAR; CRYSTALLIZATION; DESICCATION; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; DRY POWDER INHALERS; EXCIPIENTS; PARTICLE SIZE; PHYSICOCHEMICAL PROCESSES; POWDERS; RIFAMPIN; SOLUBILITY;

EID: 79960584245     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2011.02.004     Document Type: Article

References (47)

1. Rifampin Tuberculosis 88 2 2008 151 154
2. J. Schreiber, G. Zissel, U. Greinert, M. Schlaak, and J. Muller-Quernheim Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs European Journal of Medicinal Chemistry 4 2 1999 67 71
3. P. O'Hara, and A.J. Hickey Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization Pharmaceutical Research 17 8 2000 955 961
4. J.C. Sung, D.J. Padilla, L. Garcia-Contreras, J.L. VerBerkmoes, D. Durbin, C.A. Peloquin, K.J. Elbert, A.J. Hickey, and D.A. Edwards Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery Pharmaceutical Research 26 8 2009 1847 1855
5. S. Suarez, P. O'Hara, M. Kazantseva, C.E. Newcomer, R. Hopfer, D.N. McMurray, and A.J. Hickey Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model Pharmaceutical Research 18 9 2001 1315 1319 (Pubitemid 32846326)
6. S. Suarez, P. O'Hara, M. Kazantseva, C.E. Newcomer, R. Hopfer, D.N. McMurray, and A.J. Hickey Airways delivery of rifampicin microparticles for the treatment of tuberculosis Journal of Antimicrobial Chemotherapy 48 3 2001 431 434 (Pubitemid 32898818)
7. R. Sharma, D. Saxena, A.K. Dwivedi, and A. Misra Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis Pharmaceutical Research 18 10 2001 1405 1410 (Pubitemid 32977245)
8. S.P. Vyas, M.E. Kannan, S. Jain, V. Mishra, and P. Singh Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages International Journal of Pharmaceutics 269 1 2004 37 49 (Pubitemid 38035210)
9. F. Tewes, J. Brillault, W. Couet, and J.C. Olivier Formulation of rifampicin-cyclodextrin complexes for lung nebulization Journal of Controlled Release 129 2 2008 93 99
10. F. Ito, and K. Makino Preparation and properties of monodispersed rifampicin-loaded poly(lactide-co-glycolide) microspheres Colloids and Surfaces B - Biointerfaces 39 1-2 2004 17 21 (Pubitemid 39473348)
11. C. Becker, J.B. Dressman, H.E. Junginger, S. Kopp, K.K. Midha, V.P. Shah, S. Stavchansky, and D.M. Barends Biowaiver monographs for immediate release solid oral dosage forms: rifampicin Journal of Pharmaceutical Sciences 98 7 2009 2252 2267
12. H.K. Chan What is the role of particle morphology in pharmaceutical powder aerosols? Expert Opinion on Drug Delivery 5 8 2008 909 914
13. D. Traini, P.M. Young, F. Thielmann, and M. Acharya The influence of lactose pseudopolymorphic form on salbutamol sulfate-lactose interactions in DPI formulations Drug Development and Industrial Pharmacy 34 9 2008 992 1001
14. H.K. Chan Dry powder aerosol drug delivery - opportunities for colloid and surface scientists Colloids and Surfaces A - Physicochemical and Engineering Aspects 284 2006 50 55
15. X.M. Zeng, G.P. Martin, C. Marriott, and J. Pritchard The effects of carrier size and morphology on the dispersion of salbutamol sulphate after aerosolization at different flow rates Journal of Pharmacy and Pharmacology 52 10 2000 1211 1221
16. S. Adi, H. Adi, P. Tang, D. Traini, H.K. Chan, and P.M. Young Micro-particle corrugation, adhesion and inhalation aerosol efficiency European Journal of Pharmaceutical Sciences 35 1-2 2008 12 18
17. N.Y.K. Chew, and H.K. Chan Use of solid corrugated particles to enhance powder aerosol performance Pharmaceutical Research 18 11 2001 1570 1577 (Pubitemid 33022413)
18. N. Islam, P. Stewart, I. Larson, and P. Hartley Surface roughness contribution to the adhesion force distribution of salmeterol xinafoate on lactose carriers by atomic force microscopy Journal of Pharmaceutical Sciences 94 7 2005 1500 1511 (Pubitemid 41168680)
19. K. Ikegami, Y. Kawashima, H. Takeuchi, H. Yamamoto, N. Isshiki, D. Momose, and K. Ouchi Improved inhalation behavior of steroid KSR-592 in vitro with Jethaler (R) by polymorphic transformation to needle-like crystals (beta-form) Pharmaceutical Research 19 10 2002 1439 1445 (Pubitemid 35266547)
20. T.T. Hu, H. Zhao, L.C. Jiang, Y. Le, J.F. Chen, and J. Yun Engineering pharmaceutical fine particles of budesonide for dry powder inhalation (DPI) Industrial & Engineering Chemistry Research 47 23 2008 9623 9627
21. H.K. Chan, and I. Gonda Physicochemical characterization of a new respirable form of nedocromil Journal of Pharmaceutical Sciences 84 6 1995 692 696
22. H.K. Chan, and I. Gonda Respirable form of crystals of cromoglycic acid Journal of Pharmaceutical Sciences 78 2 1989 176 180 (Pubitemid 19079838)
23. M.A. Darbandi, N.A. Rouholamini, K. Gilani, and H. Tajerzadeh The effect of vehicles on spray drying of rifampicin inhalable microparticles: in vitro and in vivo evaluation Daru-Journal of Faculty of Pharmacy 16 3 2008 128 135
24. USP32-NF27 General Chapter (616), 2009.
25. D.A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. BenJebria, M.L. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer Large porous particles for pulmonary drug delivery Science 276 5320 1997 1868 1871 (Pubitemid 27443665)
26. K. Tomoda, and K. Makino Effects of lung surfactants on rifampicin release rate from monodisperse rifampicin-loaded PLGA microspheres Colloids and Surfaces B - Biointerfaces 55 1 2007 115 124 (Pubitemid 46216071)
27. Y.-J. Son, M. Horng, M. Copley, and J.T. McConville Optimization of an in vitro dissolution test method for inhalation formulations Dissolution Technologies 17 2 2010 6 13
28. Y.-J. Son, and J.T. McConville Development of a standardized dissolution test method for inhaled pharmaceutical formulations International Journal of Pharmaceutics 382 1-2 2009 15 22
29. H.G. Brittain Polymorphism in Pharmaceutical Solids 2009 Informa Healthcare New York
30. R. Hilfiker Polymorphism in the Pharmaceutical Industry 2006 Wiley-VCH Weinheim
31. K. Masters Spray Drying Handbook 1991 Longman Scientific & Technical
32. S.Q. Henwood, W. Liebenberg, L.R. Tiedt, A.P. Lotter, and M.M. de Villiers Characterization of the solubility dissolution properties of several new rifampicin polymorphs, solvate, and hydrates Drug Development and Industrial Pharmacy 27 10 2001 1017 1030 (Pubitemid 34053197)
33. G. Pelizza, M. Nebuloni, P. Ferrari, and G.G. Gallo Polymorphism of rifampicin Farmaco-Edizione Scientifica 32 7 1977 471 481 (Pubitemid 8158645)
34. S. Agrawal, Y. Ashokraj, P.V. Bharatam, O. Pillai, and R. Panchagnula Solid-state characterization of rifampicin samples and its biopharmaceutic relevance European Journal of Pharmaceutical Sciences 22 2-3 2004 127 144 (Pubitemid 38668679)
35. M.D. Louey, M. Van Oort, and A.J. Hickey Aerosol dispersion of respirable particles in narrow size distributions produced by jet-milling and spray-drying techniques Pharmaceutical Research 21 7 2004 1200 1206 (Pubitemid 38954204)
36. M.D. Louey, M. Van Oort, and A.J. Hickey Aerosol dispersion of respirable particles in narrow size distributions using drug-alone and lactose-blend formulations Pharmaceutical Research 21 7 2004 1207 1213 (Pubitemid 38954205)
37. H. Adi, D. Traini, H.K. Chan, and P.M. Young The influence of drug morphology on the aerosolisation efficiency of dry powder inhaler formulations Journal of Pharmaceutical Sciences 97 7 2008 2780 2788
38. L.A. Dellamary, T.E. Tarara, D.J. Smith, C.H. Woelk, A. Adractas, M.L. Costello, H. Gill, and J.G. Weers Hollow porous particles in metered dose inhalers Pharmaceutical Research 17 2 2000 168 174 (Pubitemid 30158365)
39. C.P. Criee, T. Meyer, W. Petro, K. Sommerer, and P. Zeising In vitro comparison of two delivery devices for administering formoterol: Foradil (R) P and formoterol ratiopharm single-dose capsule inhaler Journal of Aerosol Medicine-Deposition Clearance and Effects in the Lung 19 4 2006 466 472 (Pubitemid 46067765)
40. T. Srichana, G.P. Martin, and C. Marriott Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro European Journal of Pharmaceutical Sciences 7 1 1998 73 80 (Pubitemid 29056229)
41. N.Y.K. Chew, H.K. Chan, D.F. Bagster, and J. Mukhraiya Characterization of pharmaceutical powder inhalers: estimation of energy input for powder dispersion and effect of capsule device configuration Journal of Aerosol Science 33 7 2002 999 1008 (Pubitemid 34621344)
42. S.Q. Henwood, M.M. de Villiers, W. Liebenberg, and A.P. Lotter Solubility and dissolution properties of generic rifampicin raw materials Drug Development and Industrial Pharmacy 26 4 2000 403 408 (Pubitemid 30207711)
43. R. Panchagnula, and V. Bhardwaj Effect of amorphous content on dissolution characteristics of rifampicin Drug Development and Industrial Pharmacy 34 6 2008 642 649 (Pubitemid 351878683)
44. R. Sankar, N. Sharda, and S. Singh Behavior of decomposition of rifampicin in the presence of isoniazid in the pH range 1-3 Drug Development and Industrial Pharmacy 29 7 2003 733 738 (Pubitemid 36899879)
45. C.J. Shishoo, S.A. Shah, I.S. Rathod, S.S. Savale, J.S. Kotecha, and P.B. Shah Stability of rifampicin in dissolution medium in presence of isoniazid International Journal of Pharmaceutics 190 1 1999 109 123 (Pubitemid 29467478)
46. S. Singh, T.T. Mariappan, R. Sankar, N. Sarda, and B. Singh A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem International Journal of Pharmaceutics 228 1-2 2001 5 17 (Pubitemid 32905361)
47. H. Bhutani, T.T. Mariappan, and S. Singh The physical and chemical stability of anti-tuberculosis fixed-dose combination products under accelerated climatic conditions International Journal of Tuberculosis and Lung Disease 8 9 2004 1073 1080 (Pubitemid 39201252)